1. Omair, MA, Phumethum, V, Johnson, SR. Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis. Clin. Exp. Rheumatol. ;30 (2 Suppl 71):S55-9. . PubMed PMID:22691210 .
  2. Phumethum, V, Jamal, S, Johnson, SR. Biologic therapy for systemic sclerosis: a systematic review. J. Rheumatol. 2011;38 (2):289-96. doi: 10.3899/jrheum.100361. PubMed PMID:21041277 .
  3. Katchamart, W, Trudeau, J, Phumethum, V, Bombardier, C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. Cochrane Database Syst Rev. 2010; (4):CD008495. doi: 10.1002/14651858.CD008495. PubMed PMID:20393970 .
  4. Katchamart, W, Johnson, S, Lin, HJ, Phumethum, V, Salliot, C, Bombardier, C et al.. Predictors for remission in rheumatoid arthritis patients: A systematic review. Arthritis Care Res (Hoboken). 2010;62 (8):1128-43. doi: 10.1002/acr.20188. PubMed PMID:20235210 .
  5. Katchamart, W, Trudeau, J, Phumethum, V, Bombardier, C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 2009;68 (7):1105-12. doi: 10.1136/ard.2008.099861. PubMed PMID:19054823 PubMed Central PMC2689526.
Search PubMed